David F Candito

US Patent:

20220363707, Nov 17, 2022

Filed:

Aug 5, 2019

Appl. No.:

17/266521

Inventors:

- Rahway NJ, US
- Lucerne, CH
Craig Gibeau - Northborough MA, US
Chunhui Huang - Arlington MA, US
Shuhei Kawamura - Cambridge MA, US
David L. Sloman - Brookline MA, US
Phieng Siliphaivanh - Newton MA, US
Ryan Quiroz - Boston MA, US
Murray Wan - Watertown MA, US
Sebastian Schneider - Boston MA, US
Charles S. Yeung - Dedham MA, US
Michael H. Reutershan - Brighton MA, US
Timothy J. Henderson - Beaulieu MA, US
Jean-Laurent Paparin - Vendemian, FR
Houcine Rahali - Beaulieu, FR
Jonathan M. E. Hughes - Hoboken NJ, US
Sulagna Sanyal - Belmont MA, US
Yingchun Ye - Belmont MA, US
David A. Candito - Wrentham MA, US
Patrick S. Fier - Monroe Township NJ, US
Steven M. Silverman - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
MSD International GmbH - Lucerne

International Classification:

C07H 19/14
C07D 487/04
A61P 35/00

Abstract:

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.